Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.52 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26081038 | 0.81 | TACR1 (0.47) | TACR1HTR2CSLC6A4SLC6A2TSHR | |
| SCHEMBL5238514 | 0.80 | OPRK1 (0.41) | HTR2CHTR2BSLC6A2TAAR1ALDH1A1 | |
| SCHEMBL22728327 | 0.79 | TACR1 (0.49) | TACR1HTR2CSLC6A4HTR2BSLC6A2 | |
| Hydrochloric Acid SCHEMBL29971403 | 0.79 | OPRK1 (0.43) | HTR2CHTR2BSLC6A2TAAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20137784 | 0.79 | OPRK1 (0.43) | HTR2CHTR2BSLC6A2TAAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29453795 | 0.78 | TACR1 (0.48) | TACR1HTR2CSLC6A4HTR2BSLC6A2 | |
| Hydrochloric Acid SCHEMBL22719232 | 0.78 | TACR1 (0.48) | TACR1HTR2CSLC6A4HTR2BSLC6A2 | |
| SCHEMBL4825172 | 0.77 | SSTR4 (0.44) | TACR1HTR2CSLC6A4HTR2BMEN1 | |
| SCHEMBL10634874 | 0.76 | TACR1 (0.46) | TACR1HTR2CSLC6A4HTR2BMEN1 | |
| Hydrochloric Acid SCHEMBL20137865 | 0.76 | SSTR4 (0.43) | TACR1HTR2CSLC6A4HTR2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023102022-A1 | 4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1761539-A1 | INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER | Takeda Pharmaceutical Company Limited (JP) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005118587-A1 | INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | disclosed |
| US-6359138-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2002-03-19 | — | — | US | disclosed |
| EP-0846683-B1 | 4-Hydroxy-piperidine derivatives | HOFFMANN LA ROCHE (CH) | 2001-09-19 | — | — | EP | disclosed |
| EP-0846683-A1 | 4-Hydroxy-piperidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | IGF1R, KDR, ERBB2 | TACR1 730/4885HTR2C 345/4885SLC6A4 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.